Abstract: A girth for equine sports includes an outside, and an inside intended to rest against a horse's body. A pressure-relieving pad is arranged in the region in which the girth is intended to extend over the sternum of the horse. The pad includes a cushioning material that protrudes further inwards beyond the inside of the girth and a channel of reduced pad thickness. The cushioning material is thicker on either side of the channel, and the channel is intended to extend in front of the sternum while the cushioning material on either side of the sternum is intended to rest against the horse's body.

Abstract: A girth for equine sports includes an outside, and an inside intended to rest against a horse's body. A pressure-relieving pad is arranged in the region in which the girth is intended to extend over the sternum of the horse. The pad includes a cushioning material that protrudes further inwards beyond the inside of the girth and a channel of reduced pad thickness. The cushioning material is thicker on either side of the channel, and the channel is intended to extend in front of the sternum while the cushioning material on either side of the sternum is intended to rest against the horse's body.

Abstract: The present disclosure provides a free-standing cosmetic stick or a liquid cosmetic. The free-standing cosmetic stick or liquid cosmetic includes a bis-carboxy silicone polymer component, one or more coloring agents, and one or more constituents for rendering the formulation into a solid stick or liquid cosmetic.

Abstract: The present invention relates to methods for predicting the probability of survival of a human melanoma cancer patient based on levels of human GDF-15, and to apparatuses and kits which can be used in these methods.

Abstract: The present invention relates to monoclonal anti-human-GDF-15 antibodies. The antibodies include chimeric antibodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine antibodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.

Abstract: The present disclosure provides a free-standing cosmetic stick or a liquid cosmetic. The free-standing cosmetic stick or liquid cosmetic includes a bis-carboxy silicone polymer component, one or more coloring agents, and one or more constituents for rendering the formulation into a solid stick or liquid cosmetic.

Abstract: The present invention relates to monoclonal anti-human-GDF-15 antibodies. The antibodies include chimeric antibodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine anti bodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.

Abstract: The present invention relates to monoclonal anti-human-GDF-15 antibodies. The antibodies include chimeric anti-bodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine anti-bodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.

Abstract: The present invention relates to uses of inhibitors of human Growth and Differentiation Factor 15 (GDF-15), and to combined uses of such inhibitors with immune checkpoint blockers, in the treatment of solid cancers.

Abstract: The present invention relates to uses of inhibitors of human Growth and Differentiation Factor 15 (GDF-15), and to combined uses of such inhibitors with immune checkpoint blockers, in the treatment of solid cancers.

Abstract: A girth for equine sport includes an outside and an inside intended to rest against the horse's body. A pressure-relieving pad is arranged in the region in which the girth is intended to extend over the sternum of a horse. The pad includes a cushioning material that protrudes further inwards beyond the inside of the girth and a channel of reduced pad thickness. The cushioning material protrudes further inwards on either side of the channel than in the region of the channel such that the channel is intended to extend in front of the sternum, and the cushioning material on either side of the sternum is intended to rest against the horse's body.

Abstract: The present disclosure provides a free-standing cosmetic stick or a liquid cosmetic. The free-standing cosmetic stick or liquid cosmetic includes a bis-carboxy silicone polymer component, one or more coloring agents, and one or more constituents for rendering the formulation into a solid stick or liquid cosmetic.

Abstract: The present invention relates to methods for predicting the probability of survival of a human melanoma cancer patient based on levels of human GDF-15, and to apparatuses and kits which can be used in these methods.

Abstract: The present invention relates to monoclonal anti-human-GDF-15 antibodies. The antibodies include chimeric antibodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine anti bodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.

Abstract: The present invention relates to monoclonal anti-human-GDF-15 antibodies. The antibodies include chimeric anti-bodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine anti-bodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.

Abstract: The present invention relates to monoclonal anti-human-GDF-15 antibodies. The antibodies include chimeric antibodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine antibodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.

Abstract: The present invention relates to uses of inhibitors of human Growth and Differentiation Factor 15 (GDF-15), and to combined uses of such inhibitors with immune checkpoint blockers, in the treatment of solid cancers.

Abstract: The present invention relates to methods for predicting the probability of survival of a human melanoma cancer patient based on levels of human GDF-15, and to apparatuses and kits which can be used in these methods.

Abstract: The present invention relates to monoclonal anti-human-GDF-15 antibodies. The antibodies include chimeric antibodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine antibodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.

Abstract: The present invention relates to monoclonal anti-human-GDF-15 antibodies. The antibodies include chimeric antibodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine antibodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.